Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

A toxicokinetic statement was prepared and a conclusion of EFSA (2008) was included.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
100
Absorption rate - dermal (%):
10
Absorption rate - inhalation (%):
100

Additional information

For risk assessment purposes oral absorption of DL-alanine is set at 100%.

DL-alanine is of low volatility due to a very low vapour pressure. From this and from the particle size it is not expected that DL-alanine reaches the tracheobronchial or pulmonary region in significant amounts.

However, being a very hydrophilic substance with a molecular mass of only 89.09, any DL-alanine reaching the lungs might be absorbed through aqueous pores.

For risk assessment purposes, it is unlikely that DL-alanine will be inhaled due to its high high MMAD (Mass median aerodynamic diameter); any DL-alnine inhaled will be deposited in the upper respiratory tract and subsequently swallowed and will become orally available, as such the inhalation absorption of DL-alanine is set at 100% via the oral route.

L-alanine with high water solubility (166.5 g/L) and the log P value below 0 (-2.74) may be too hydrophilic to cross the lipid rich environment of the stratum corneum. Therefore, 10% dermal absorption of L-alanine is proposed for risk assessment purposes.